Fortress Biotech, INC 8-K filings

Fortress Biotech's board of directors has adopted amended bylaws that change the voting requirements for director elections and designate Delaware as the exclusive forum for legal disputes.

Fortress Biotech stockholders approved amendments to the company's stock incentive plans, increasing share availability and extending the long-term incentive plan.

Fortress Biotech announced a 7% year-over-year increase in product revenue for Q1 2024, driven by strong growth in flagship products and advancements in its clinical pipeline.

Fortress Biotech reported record consolidated net revenue of $84.5 million for 2023 and highlighted progress on multiple regulatory fronts, including an accepted NDA for DFD-29.

Fortress Biotech announces that director Eric Rowinsky will not seek re-election at the 2024 annual meeting due to other professional commitments, but will remain as a consultant.